Home > Search Results

Results: 4

Treatment of Barrett's oesophagus

One of the two main types of oesophageal (gullet) cancer, oesophageal adenocarcinoma, is rapidly increasing in incidence in the western world. The prognosis for patients treated for oesophageal adenocarcinoma is appalling with fewer than 15% of individuals surviving beyond five years. Barrett’s oesophagus has been identified as the pre‐cancerous stage of adenocarcinoma. It is recognised that Barrett's oesophagus develops as a complication of acid and bile reflux which commonly, but not inevitably, leads to heartburn symptoms. In response to these injurious agents, the normal squamous lining of the oesophagus is replaced by a columnar lining resembling the lining of the intestine. This intestinal subtype has the highest risk of malignancy and the term Barrett's oesophagus is used only for this subtype in many areas of the world, and in most research publications. Barrett's oesophagus can gradually progress to adenocarcinoma through a series of stages called dysplasia which can be identified in biopsies examined under the microscope.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus

Barrett’s oesophagus develops as a consequence of chronic gastro-oesophageal reflux disease. It is characterised by abnormal changes in the oesophageal lining that may, in some patients, become dysplastic and lead to oesophageal cancer. Oesophagectomy (surgical removal of the oesophagus) is the standard NHS treatment for high-grade dysplastic Barrett’s oesophagus or intramucosal cancer (including T1a); however, it is associated with significant mortality and morbidity. Consequently less invasive surgical techniques, such as endoscopic mucosal resection, and ablative treatments have been developed and are being used as alternatives for patients who are unsuitable for surgery or who express a preference for less invasive options. However, in the past there has been uncertainty whether ablative therapy for Barrett’s oesophagus is both clinically and cost effective compared with other management options.

NICE Clinical Guidelines - National Institute for Health and Clinical Excellence (UK).

Version: August 2010
Show search results within this document

Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy

This review found that endoscopic treatments offered safe and effective alternatives to oesophagectomy in patients with Barrett's oesophagus and high-grade dysplasia. The evidence did not answer the question regarding the comparison of oesophagectomy with endoscopic treatments, but the authors' conclusions on the shortcomings of the included trials and the inability to ascertain the most effective endoscopic treatment seem appropriate.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Effectiveness, safety, and cost-effectiveness of photodynamic therapy in Barrett's esophagus: a systematic review

This review concluded that photodynamic therapy was effective in the ablation of dysplasia in Barrett's oesophagus, but evidence for its effectiveness compared with other endoscopic techniques or oesophagectomy was insufficient and inconclusive. In view of the poor quality and conflicting results of the included studies this conclusion appears appropriate, although other relevant studies may have been missed.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Systematic Reviews in PubMed

See all (5)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...